{"product_id":"cancer-vaccines-markets","title":"Cancer Vaccines Markets","description":"\u003cp\u003e\u003cstrong\u003eCancer Vaccines: Market Forecast, Competitive Landscape and Strategic Opportunities, 2027–2031\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlobal forecasts by vaccine type, technology, indication, product and route of administration, with country and regional breakouts and 10 company profiles.\u003c\/p\u003e\n\u003cdiv style=\"margin:24px 0;padding:20px 24px;border:2px solid #1f3a5f;border-radius:8px;text-align:center;\"\u003e\n\u003cp style=\"margin:0 0 6px;font-size:1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin:0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCVACC\" style=\"display:inline-block;padding:12px 28px;background:#1f3a5f;color:#ffffff;text-decoration:none;border-radius:6px;font-weight:bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eOur Take\u003c\/h3\u003e\n\u003cp\u003eCancer vaccines are turning therapeutic. Preventive HPV and hepatitis B vaccines make up 92% of a $6.1 billion market in 2026, but therapeutic vaccines rise from 8% to 26% of a $9.5 billion market by 2031. The turning point is Moderna and Merck's intismeran: full Phase 3 data presented at ESMO in October 2026 showed a 42% reduction in the risk of melanoma recurrence or death, and this report forecasts it at $1.0 billion in 2031. Meanwhile Gardasil, still by far the largest product, is resetting after losing its China business.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCVACC_Key_Graphic.png?v=1793128922\" alt=\"Cancer vaccines turn therapeutic: cancer vaccine market by vaccine type, 2026 to 2031\" style=\"width:100%;height:auto;\"\u003e\u003c\/p\u003e\n\u003ch3\u003eSituation Analysis: what is really happening\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGardasil is resetting. \u003c\/strong\u003eSales fell 39% to $5.2 billion in 2025 as demand collapsed in China. This report forecasts $4.8 billion in 2026, recovering slowly to $5.6 billion in 2031, while lower-priced HPV vaccines grow from $650 million to $1.0 billion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndividualized mRNA vaccines have arrived. \u003c\/strong\u003eIntismeran plus Keytruda reduced the risk of recurrence or death by 42% (hazard ratio 0.58) in the Phase 3 INTerpath-001 trial. Neoantigen vaccines grow from almost nothing to $1.1 billion, 12% of the market in 2031.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMelanoma leads, lung cancer is the bigger prize. \u003c\/strong\u003eMelanoma becomes the largest therapeutic vaccine indication, rising from $61 million to $1.2 billion, and non-small cell lung cancer reaches $333 million.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNot every vaccine will work. \u003c\/strong\u003eBioNTech stopped its colorectal cancer trial of autogene cevumeran in August 2026, and IO Biotech is exploring strategic alternatives after the FDA advised against filing its melanoma vaccine.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBCG is a supply story. \u003c\/strong\u003eBCG revenue grows from $232 million to $551 million, but Merck has delayed its new BCG plant into 2027 while Anktiva's expanded approval adds demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompany Analysis: who is positioned, who is exposed\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMerck \u0026amp; Co.: \u003c\/strong\u003eThe largest company in the market, combining Gardasil, the sole U.S. supply of TICE BCG and a share of intismeran, which it aims to use with Keytruda to extend its oncology leadership beyond Keytruda's patent expiries.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModerna: \u003c\/strong\u003eCo-developer of intismeran, the first individualized neoantigen or mRNA cancer therapy to succeed in Phase 3, with nine Phase 2 and 3 INTerpath trials across melanoma, lung, bladder and kidney cancer. It must now scale individualized manufacturing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBioNTech: \u003c\/strong\u003eDevelops individualized and off-the-shelf mRNA vaccines, but stopped its colorectal cancer trial of autogene cevumeran in August 2026; the pancreatic cancer trial continues.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWantai BioPharm: \u003c\/strong\u003eCecolin 9, the first Chinese 9-valent HPV vaccine, priced about 60% below Gardasil 9 in China, leads the challenge from lower-priced HPV vaccines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunityBio: \u003c\/strong\u003eAnktiva's October 2026 expanded approval and recombinant BCG from the Serum Institute of India position it to address BCG shortages.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOSE Immunotherapeutics: \u003c\/strong\u003eTedopi, an off-the-shelf neoepitope vaccine, is close to full enrolment in its registrational Phase 3 lung cancer trial, but cash runway is confirmed only through December 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePlus 4 more company profiles covering established vaccine and immunotherapy makers and low-cost vaccine suppliers.\u003c\/p\u003e\n\u003ch3\u003eQuestions this report answers\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eHow quickly can intismeran turn one positive Phase 3 trial into a broad franchise?\u003c\/li\u003e\n\u003cli\u003eWill individualized vaccines work beyond melanoma, especially in lung cancer?\u003c\/li\u003e\n\u003cli\u003eHow far will Gardasil recover after losing its China business?\u003c\/li\u003e\n\u003cli\u003eHow fast will lower-priced Chinese and Indian HPV vaccines take share?\u003c\/li\u003e\n\u003cli\u003eHow long will BCG shortages last, and who benefits?\u003c\/li\u003e\n\u003cli\u003eWhich off-the-shelf therapeutic vaccines can reach the market by 2031?\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhat’s inside\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e163 pages, 23 chapters, 36 tables and 56 figures\u003c\/li\u003e\n\u003cli\u003e10 company profiles with technology, pipeline, strategy and risks\u003c\/li\u003e\n\u003cli\u003eForecasts 2027–2031 from a 2026 base (actual) year, by vaccine type, technology, indication, product and route of administration, for 14 countries and regions\u003c\/li\u003e\n\u003cli\u003eApproved product registry, 2025 sales benchmarks and the full ESMO 2026 intismeran data\u003c\/li\u003e\n\u003cli\u003eClinical pipeline, manufacturing and BCG supply, regulatory pathways, and a China ecosystem chapter\u003c\/li\u003e\n\u003cli\u003eDelivered as 3 files: full report PDF, Situation Analysis PDF, and Excel workbook of all charts and tables\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCVACC_1026_Table_of_Contents.pdf?v=1793128922\" target=\"_blank\" rel=\"noopener\"\u003eDownload the Table of Contents (PDF)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin:24px 0;padding:20px 24px;border:2px solid #1f3a5f;border-radius:8px;text-align:center;\"\u003e\n\u003cp style=\"margin:0 0 6px;font-size:1.15em;\"\u003e\u003cstrong\u003eSee inside before you buy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp style=\"margin:0 0 16px;\"\u003eGet a free sample: the full table of contents plus real pages of analysis, company profiles, tables and charts.\u003c\/p\u003e\n\u003cp style=\"margin:0;\"\u003e\u003ca href=\"\/pages\/request-a-sample?report=ONCVACC\" style=\"display:inline-block;padding:12px 28px;background:#1f3a5f;color:#ffffff;text-decoration:none;border-radius:6px;font-weight:bold;\"\u003eRequest a free sample\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eWho buys this report\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBusiness development teams: \u003c\/strong\u003etrack which vaccine platforms and tumor types are winning, and who leads each.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestors and equity analysts: \u003c\/strong\u003emodel intismeran's launch, Gardasil's recovery and the BCG supply gap.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVaccine developers: \u003c\/strong\u003echoose the technologies, indications and combinations with the most room to grow.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVaccine manufacturers and suppliers: \u003c\/strong\u003esize HPV price competition and the BCG and individualized manufacturing opportunity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eLicences and support\u003c\/h3\u003e\n\u003cp\u003eYour order is delivered to your inbox immediately. Every licence includes unlimited questions to the analyst and custom data breakouts, including any country not shown. Single User, Five User and Enterprise licences contain the same report; they differ only in how many people may use it.\u003c\/p\u003e\n\u003ch3\u003eAbout the author\u003c\/h3\u003e\n\u003cp\u003eGreg Powell, B.Sc., M.B.A., has worked in laboratory testing and management for more than 20 years, with executive training at Harvard Business School and the Burke Institute.\u003c\/p\u003e","brand":"OncoPharma Insights","offers":[{"title":"Single User","offer_id":67890738397263,"sku":null,"price":6995.0,"currency_code":"USD","in_stock":true},{"title":"Five User","offer_id":67890738430031,"sku":null,"price":9995.0,"currency_code":"USD","in_stock":true},{"title":"Enterprise License","offer_id":67890738462799,"sku":null,"price":13995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0735\/8244\/4623\/files\/ONCVACC_1026_Cover.png?v=1793128922","url":"https:\/\/oncopharmainsights.com\/products\/cancer-vaccines-markets","provider":"OncoPharma Insights","version":"1.0","type":"link"}